ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconIcon FacebookIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Science

Kyoto researchers show gene fix may work

OSAKA -- Kyoto University scientists have found that correcting a genetic defect that causes muscular dystrophy can alleviate the symptoms of the severest form of this debilitating disease.

     Akitsu Hotta and his colleagues used induced pluripotent stem (iPS) cells -- cells reprogrammed to an embryonic state -- to test their hypothesis. While much work remains to turn their discovery into a practical treatment, it does give cause for hope.

     Their findings appear Thursday in the online version of the journal Stem Cell Reports.

     Scientists have known that Duchenne muscular dystrophy, an incurable condition that leads to respiratory and cardiac failure, is the result of a genetic mutation that disrupts the production of a crucial protein.

     The Kyoto University team took iPS cells derived from patient tissue, removed the defective genetic sequence and replaced it with a normal one. When these cells turned into muscle cells, they produced the protein correctly. But iPS cells that did not undergo the genetic repair yielded muscle cells that soon degenerated.

(Nikkei)

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

{{sentenceStarter}} {{numberReadArticles}} free article{{numberReadArticles-plural}} this month

Stay ahead with our exclusives on Asia; the most dynamic market in the world.

Benefit from in-depth journalism from trusted experts within Asia itself.

Try 3 months for $9

Offer ends September 30th

Your trial period has expired

You need a subscription to...

See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

See all offers
NAR on print phone, device, and tablet media